Common prosperity is an essential requirement of socialism, and promoting the high-quality development of healthcare security is an important task of common prosperity. Currently, the contradiction between the overall insufficient supply of health services in China and the continuous growth of people's demand for medical services is still prominent. Especially for small groups with low incidence rate, the prominent problem is that there are only a few alternative drugs with high price. How to ensure the drug demand of the small groups and reduce their disease burden is an important topic of improving health equity and achieving common prosperity in China. At present, many countries are exploring a special fund guarantee model to handle the potential contradiction between the high-value drug needs of small groups with extremely heavy disease burden and economic burden, and the basic drug needs of the majority of the insured. Among them, the high-value innovative drug guarantee special fund model explored by the UK from the Cancer Drug Fund is the most typical one. Therefore, the article analyzes the UK's high-value innovative drug payment guarantee mechanism from the perspective of the payment side, including drug access and exit mechanism, fund raising and risk control mechanism, data collection and management mechanism, and summarizes its characteristics of independent financing, transition, additional condition, controllability, and multi-dimensional management.